February 16 Biotech Update

There has been some interesting news to end the week. The market seems to have recovered its footing a little and this includes the sector. There is still some work to be done to repair the damage of the sell off but so far so good. 1. NBIX has been interesting. I thought it would […]

February 2 Biotech Update

It looks like the correction continues. Fundamental news does not seem to be matter a lot this week, which seems like typical price action during a correction. This does not seem sector specific and I doubt that it becomes anything more than a correction in a larger bull market but that does not mean it […]

January 31 Biotech Update

We had a nice little correction yesterday but while it was certainly a meaningful move compared to recent price action, it did not really remove any of the real fluff in the sector. That being said it could be enough to reset the “over bought” conditions and lead to a continuation of the rally. While […]

January 30 Biotech Update

The sector remains strong. The market has weakened a little but the sector was still holding on. If the broader market weakness continues, it will eventually drag down the sector but that has not happened yet. Of course, a bit of a pullback is well overdue and will happen eventually but the trigger and timing […]

January 25 Biotech Update

We are getting some biotech earnings but nothing that is dramatically thesis changing. We had a little consolidation yesterday and I would not be surprised to see it continue but the trend remains higher and suspect that we break into new highs in the first quarter (assuming at least a benign general market environment). 1. […]

December 15 Biotech Update

The question I keep asking myself is whether or not JPM really will be the positive catalyst that everyone is expecting (or really hoping for). We know that companies tend to save good news for JPM and good news should push stocks higher especially if they have been lagging. While I understand that logic, I […]

December 14 Biotech Update

Volume and news is starting to dry up but there were some interesting tidbits to talk about but they are more interesting than really game changing. In any case, we are quickly approach the holiday lull but on the positive side that means we are closer to the JPM rush of news. 1. CLLS reported […]

November 13 Biotech Update

Another week and another noticeable lack of M&A. At this point, we are so use to nothing happening that it seems like a normal week (which it is). Even though I enter every week with the expectation that nothing will be done, it still surprises me that the large caps that are getting destroyed because […]

October 13 Biotech Update

More of the same with winners drifting higher in the sector and losers drifting lower. I had hoped that volume and interest would have picked up this week but it is looking more and more like we will need earning season and the conferences to drive any sort of interest. Luckily both are fast approaching. […]

October 10 Biotech Update

I was in my office yesterday to write but there is really nothing happening in the sector that is exceptionally newsworthy. I was hoping we would have some news today but it looks like we are in a bit of a lull. The good news is that it will not last too much longer as […]

September 15 Biotech Update

It still looks to me that the sector is acting less like a sector and more like an aggregation of individual stocks. That is always true (it is not a stock market but a market of stocks) but usually there is a rising (or lowering) tide that raises (or lowers) all boats effect. I find […]

June 1 Biotech Update

The sector sort of had some positive news yesterday with TSRO putting itself on the proverbial block. This obviously moved TSRO and sector as it reminded people that good things might happen as well. Given that this was meaningful for the sector (and the lack of other news) I want to focus on a couple […]

May 3 Biotech Update

I missed yesterday at home with a sick child. I need to catch up a little on what I missed but I wanted to follow up on the GILD quarter as it is an interesting case for a number of reasons. 1. The revenues were awful. Just about every part of the GILD business is […]

April 26 Biotech Update

Today is the eye in the center of the storm with a number of earnings tomorrow. It might also be the eye in the center of the North Korean crisis as Trump is meeting with all of the Senate and House to discuss the situation. If we can get through the next couple days without […]

March 15 Biotech Update

The PARP wars have ramped up with the AZN data. This was important data for the PARP wars but sort of important for the sector more broadly as this is a new class of drugs that seemingly has an impressive impact on the lives of patients. I think the PCSK9 data later this week are […]

February 22 Biotech Update

A little bit of news since yesterday and I will focus on them but more broadly the sector seemed to struggle yesterday. It had been outperforming so a day of relative weakness is not unexpected but was certainly a sell biotech and buy everything else sort of day. Let us see if that pattern continues […]

February 17 Biotech Update

Some news to talk about today in a couple stocks and one idea I want to float that has been ruminating in my mind. The sector continues to do well as is the market in general. There has been some talk that the melt up is related to a massive synthetic short position in the […]

February 15 Biotech Update

We have some additional news yesterday but nothing that is necessarily positive for the sector. It certainly rallied in the afternoon and I suspect there is enough juice left for that to continue. Of course, we are only one tweet away from a pullback but I guess that is true of every sector and stock. […]

February 10 Biotech Update

So I think we need to be prepared for some more backlash and bad press given the decision by Marathon to think it is business as usual. So far the backlash has been isolated but it is difficult to see this not become a political talking point. 1. Marathon licensed an old, generic steroid (DFZ) […]

January 31 Biotech Update

We had some earnings but the real potential mover of the sector is the meeting this morning with Trump. The headlines are still early but it looks like a net positive for the sector but we will see how it is interpreted. If history repeats these meetings tend to see some minor announced concession in […]